evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

52 questions · 52 findings · 5 reviews · Metabolic and Endocrine Disorders

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 16 · 30.8%GRADE not reported 1 · 1.9%Very low 13 · 25%Low 13 · 25%Moderate 9 · 17.3%High 0 · 0%

Intervention not reported

Non‐fatal macrovascular outcomes 1. Composite a. Intervention vs metformin [1a. 6 months to 4 years] b. Intervention vs thiazolidinediones [1b. 52 weeks to 4 years] c. Intervention vs meglitinide [1c. 12 months to 15 months]2. Non‐fatal myocardial... · participants with type 2 diabetes mellitus

The intervention may leads to lower non‐fatal macrovascular outcomes 1. Composite a. Intervention vs… (low certainty).

1 finding from 1 review

Intervention not reported

Cancer a. Intervention vs thiazolidinediones [52 weeks to 4 years] b. Intervention vs insulin [6 years to 10 years] · participants with type 2 diabetes mellitus

The intervention showed no clear difference in cancer a. Intervention vs thiazolidinediones [52 weeks to 4 years]… (low certainty).

1 finding from 1 review

Intervention not reported

Health‐related quality of life a. Intervention vs thiazolidinediones [12 months] b. Intervention vs insulin [6 years] c. Intervention vs alpha‐glucosidase inhibitors [12 months] · participants with type 2 diabetes mellitus
1 finding from 1 review

Intervention not reported

Adverse events 1. All adverse events 2. Drop‐outs due to adverse events Interventions vs thiazolidinediones [1. 6 months to 12 months] [2. 24 weeks to 52 weeks] · participants with type 2 diabetes mellitus

The intervention may leads to lower adverse events 1. All adverse events 2. Drop‐outs due to adverse… (low certainty).

1 finding from 1 review

Intervention not reported

All‐cause mortality a. Intervention vs metformin [a. 24 weeks to 4 years] b. Intervention vs thiazolidinediones [b. 24 weeks to 4 years] c. Intervention vs insulin [c. 9 months to 10 years] d. Intervention vs incretin‐based control [d. 52 weeks to... · participants with type 2 diabetes mellitus

The intervention showed no clear difference in all‐cause mortality a. Intervention vs metformin [a. 24 weeks to 4… (low certainty).

1 finding from 1 review

Intervention not reported

Cardiovascular mortality a. Intervention vs metformin [a. 24 weeks to 4 years] b. Intervention vs thiazolidinediones [b. 24 weeks to 4 years] c. Intervention vs insulin [c. 9 months to 10 years] d. Intervention vs meglitinide [d. 12 months to 17 m... · participants with type 2 diabetes mellitus

The intervention showed no clear difference in cardiovascular mortality a. Intervention vs metformin [a. 24 weeks… (low certainty).

1 finding from 1 review